Inhibition of local aldosterone by eplerenone reduces renal structural damage in a novel model of chronic cyclosporine A nephrotoxicity

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

Volumn 16, Issue 2, 2015, Pages 301-310

  Sun, Qiao Ling ^a   Li, Meng ^a   Rui, Hong Liang ^b   Chen, Yi Pu ^b  

^a SHANDONG UNIVERSITY   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Aldosterone; calcineurin inhibitor; cyclosporine; mineralocorticoid receptor antagonist; nephrotoxicity; tubulointerstitial fibrosis

Indexed keywords

ALDOSTERONE; COLLAGEN TYPE 1; CONNECTIVE TISSUE GROWTH FACTOR; CYCLOSPORIN A; EPLERENONE; PLASMINOGEN ACTIVATOR INHIBITOR 1; POTASSIUM; SODIUM; TRANSFORMING GROWTH FACTOR BETA1; ALDOSTERONE SYNTHASE; CYCLOSPORIN; ELECTROLYTE; MESSENGER RNA; SPIRONOLACTONE;

ALDOSTERONE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CREATININE CLEARANCE; HISTOPATHOLOGY; HORMONE INHIBITION; HORMONE SYNTHESIS; HYPERKALEMIA; HYPONATREMIA; KIDNEY FIBROSIS; KIDNEY FUNCTION; KIDNEY INJURY; KIDNEY STRUCTURE; MALE; NATRIURESIS; NEPHROTOXICITY; NONHUMAN; POTASSIUM BLOOD LEVEL; POTASSIUM URINE LEVEL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN URINE LEVEL; RAT; SODIUM BLOOD LEVEL; SODIUM URINE LEVEL; UPREGULATION; ADRENALECTOMY; ANALOGS AND DERIVATIVES; ANIMAL; BLOOD; CHEMICALLY INDUCED; CHRONIC DISEASE; DISEASE MODEL; DRUG EFFECTS; FIBROSIS; GENETICS; KIDNEY; KIDNEY DISEASE; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; SPRAGUE DAWLEY RAT; URINE;

ADRENALECTOMY; ALDOSTERONE; ANIMALS; CHRONIC DISEASE; CYCLOSPORINE; CYTOCHROME P-450 CYP11B2; DISEASE MODELS, ANIMAL; ELECTROLYTES; FIBROSIS; KIDNEY; KIDNEY DISEASES; MALE; POTASSIUM; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER; SODIUM; SPIRONOLACTONE;

EID: 84930915402     PISSN: 14703203     EISSN: 17528976     Source Type: Journal    
DOI: 10.1177/1470320314561248     Document Type: Article

References (56)

1. Thomson AW, McAuley FT, Whiting PH, et al. Angiotensin-converting enzyme inhibition or aldosterone antagonism reduces cyclosporine nephrotoxicity in the rat. Transplant Proc. 1987 ; 19: 1242-1243
2. McMorrow T, Gaffney MM, Slattery C, et al. Cyclosporine A induced epithelial-mesenchymal transition in human renal proximal tubular epithelial cells. Nephrol Dial Transplant. 2005 ; 20: 2215-2225
3. Shihab FS, Andoh TF, Tanner AM, et al. Salt-depletion enhances TGF-β1 and matrix proteins expression in rat chronic cyclosporine nephropathy. Am J Kidney Dis. 1997 ; 30: 71-81
4. Laiho M, Saksela O, Keski-Oja J, et al. Transforming growth factor-β induction of type-I plasminogen activator inhibitor. J Biol Chem. 1987 ; 262: 17467-17474
5. Okada H, Watanabe Y, Kikuta T, et al. Bradykinin decreases plasminogen activator inhibitor-1 expression and facilitates matrix degradation in the renal tubulointerstitium under angiotensin-converting enzyme blockade. J Am Soc Nephrol. 2004 ; 15: 2404-2413
6. Islam M, Burke JF, McGowan TA, et al. Effect of anti-transforming growth factor-beta antibodies in cyclosporine-induced renal dysfunction. Kidney Int. 2001 ; 59: 498-506
7. Del Vecchio L, Procaccio M, Vigano S, et al. Mechanisms of disease: The role of aldosterone in kidney damage and clinical benefits of its blockade. Nat Clin Pract Nephrol. 2007 ; 3: 42-49
8. Nagase M, Fujita T. Aldosterone and glomerular podocyte injury. Clin Exp Nephrol. 2008 ; 12: 233-242
9. Nishiyama A, Abe Y. Molecular mechanisms and therapeutic strategies of chronic renal injury: Renoprotective effects of aldosterone blockade. J Pharmacol Sci. 2006 ; 100: 9-16
10. Lea WB, Kwak ES, Luther JM, et al. Aldosterone antagonism or synthase inhibition reduces end-organ damage induced by treatment with angiotensin and high salt. Kidney Int. 2009 ; 75: 936-944
11. Cortinovis M, Perico N, Cattaneo D, et al. Aldosterone and progression of kidney disease. Ther Adv Cardiovasc Dis. 2009 ; 3: 133-143
12. Bomback AS, Klemmer PJ. Renal injury in extreme obesity: The important role of aldosterone. Kidney Int. 2008 ; 74: 1216-1217
13. Lakkis J, Lu WX, Weir MR. RAAS escape: A real clinical entity that may be important in the progression of cardiovascular and renal disease. Curr Hypertens Rep. 2003 ; 5: 408-417
14. Han KH, Kang YS, Han SY, et al. Spironolactone ameliorates renal injury and connective tissue growth factor expression in type II diabetic rats. Kidney Int. 2006 ; 70: 111-120
15. Schjoedt KJ, Andersen S, Rossing P, et al. Aldosterone escape during blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate. Diabetologia. 2004 ; 47: 1936-1939
16. Bertocchio JP, Warnock DG, Jaisser F. Mineralocorticoid receptor activation and blockade: An emerging paradigm in chronic kidney disease. Kidney Int. 2011 ; 79: 1051-1060
17. Brown NJ, Nakamura S, Ma L, et al. Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo. Kidney Int. 2000 ; 58: 1219-1227
18. Kawarazaki H, Ando K, Fujita M, et al. Mineralocorticoid receptor activation: A major contributor to salt-induced renal injury and hypertension in young rats. Am Physiol Renal Physiol. 2011 ; 300: F1402 - F1409
19. Ortiz RM, Graciano ML, Mullins JJ, et al. Aldosterone receptor antagonism alleviates proteinuria, but not malignant hypertension, in Cyp1a1-Ren2 transgenic rats. Am J Physiol Renal Physiol. 2007 ; 293: F1584 - F1591
20. Wei J, Li C, Ma C, et al. Rho kinase pathway is likely responsible for the profibrotic actions of aldosterone in renal epithelial cells via inducing epithelial-mesenchymal transition and extracellular matrix excretion. Cell Biol Int. 2013 ; 37: 725-730
21. Whaley-Connell AT, Habibi J, Nistala R, et al. Mineralocorticoid receptor-dependent proximal tubule injury is mediated by a redox-sensitive mTOR/S6K1 pathway. Am J Nephrol. 2012 ; 35: 90-100
22. Nagai Y, Miyata K, Sun GP, et al. Aldosterone stimulates collagen gene expression and synthesis via activation of ERK1/2 in rat renal fibroblasts. Hypertension. 2005 ; 46: 1039-1045
23. Huang LL, Nikolic-Paterson DJ, Ma FY, et al. Aldosterone induces kidney fibroblast proliferation via activation of growth factor receptors and PI3K/MAPK signalling. Nephron Exp Nephrol. 2012 ; 120: e115 - e122
24. Lai L, Chen J, Hao CM, et al. Aldosterone promotes fibronectin production through a Smad2-dependent TGF-beta1 pathway in mesangial cells. Biochem Biophys Res Commun. 2006 ; 348: 70-75
25. Luo Y, Chen YP. Influence of endothelin on local aldosterone production synthesized by human renal tubular cells. Zhonghua Yi Xue Za Zhi. 2005 ; 85: 2070-2075
26. Terada Y, Kobayashi T, Kuwana H, et al. Aldosterone stimulates proliferation of mesangial cells by activating mitogen-activated protein kinase 1/2, cyclin D1, and cyclin A. J Am Soc Nephrol. 2005 ; 16: 2296-2305
27. Xue C, Siragy HM. Local renal aldosterone system and its regulation by salt, diabetes, and angiotensin II type 1 receptor. Hypertension. 2005 ; 46: 584-590
28. Lee SH, Yoo TH, Nam BY, et al. Activation of local aldosterone system within podocytes is involved in apoptosis under diabetic conditions. Am J Physiol Renal Physiol. 2009 ; 297: F1381 - F1390
29. Siragy HM, Xue C. Local renal aldosterone production induces inflammation and matrix formation in kidneys of diabetic rats. Exp Physiol. 2008 ; 93: 817-824
30. Taira M, Toba H, Murakami M, et al. Spironolactone exhibits direct renoprotective effects and inhibits renal renin-angiotensin-aldosterone system in diabetic rats. Eur J Pharmacol. 2008 ; 589: 264-271
31. Feria I, Pichardo I, Juárez P, et al. Therapeutic benefit of spironolactone in experimental chronic cyclosporine A nephrotoxicity. Kidney Int. 2003 ; 63: 43-52
32. Pérez-Rojas JM, Derive S, Blanco JA, et al. Renocortical mRNA expression of vasoactive factors during spironolactone protective effect in chronic cyclosporine nephrotoxicity. Am J Physiol Renal Physiol. 2005 ; 289: F1020 - F1030
33. Batlle DC. Sodium-dependent urinary acidification in patients with aldosterone deficiency and in adrenalectomized rats: Effect of furosemide. Metabolism. 1986 ; 35: 852-860
34. Stanton B, Giebisch G, Klein-Robbenhaar G, et al. Effects of adrenalectomy and chronic adrenal corticosteroid replacement on potassium transport in rat kidney. J Clin Invest. 1985 ; 75: 1317-1326
35. Young BA, Burdmann EA, Johnson R. Cellular proliferation and macrophage influx precede interstitial fibrosis in cyclosporine nephrotoxicity. Kidney Int. 1995 ; 48: 439-448
36. Rosen S, Greenfeld Z, Brezis M.. Chronic cyclosporine-induced nephropathy in the rat. A medullary ray and inner stripe injury. Transplantation. 1990 ; 49: 445-452
37. Elzinga LW, Rosen S, Bennett WM. Dissociation of glomerular filtration rate from tubulointerstitial fibrosis in experimental chronic cyclosporine nephropathy: Role of sodium intake. J Am Soc Nephrol. 1993 ; 4: 214-221
38. Silva FM, Miorin LA, Sens YA. The effect of aldosterone antagonist in experimental nephropathy induced by cyclosporine A. Ren Fail. 2008 ; 30: 439-442
39. Ling H, Li X, Jha S, et al. Therapeutic role of TGF-beta-neutralizing antibody in mouse cyclosporin A nephropathy: Morphologic improvement associated with functional preservation. J Am Soc Nephrol. 2003 ; 14: 377-388
40. Shihab FS, Bennett WM, Yi H, et al. Effect of cyclosporine and sirolimus on the expression of connective tissue growth factor in rat experimental chronic nephrotoxicity. Am J Nephrol. 2006 ; 26: 400-407
41. Lassila M, Finckenberg P, Pere AK, et al. Comparison of enalapril and valsartan in cyclosporine A-induced hypertension and nephrotoxicity in spontaneously hypertensive rats on high-sodium diet. Br J Pharmacol. 2000 ; 130: 1339-1347
42. Boesby L, Elung-Jensen T, Klausen TW, et al. Moderate antiproteinuric effect of add-on aldosterone blockade with eplerenone in non-diabetic chronic kidney disease. A randomized cross-over study. PLoS One. 2011 ; 6: e26904
43. Leask A, Abraham DJ. The role of connective tissue growth factor, a multifunctional matricellular protein, in fibroblast biology. Biochem Cell Biol. 2003 ; 81: 355-363
44. Moussad EE, Brigstock DR. Connective tissue growth factor: What's in a name?. Mol Genet Metab. 2000 ; 71: 276-292
45. McMorrow T, Gaffney MM, Slattery C, et al. Cyclosporine A induced epithelial-mesenchymal transition in human renal proximal tubular epithelial cells. Nephrol Dial Transplant. 2005 ; 20: 2215-2225
46. Saksela O, Rifkin DB. Cell-associated plasminogen activation: Regulation and physiologic functions. Annu Rev Cell Biol. 1988 ; 4: 93-126
47. Bobadilla NA, Gamba G, Tapia E, et al. Role of NO in cyclosporin nephrotoxicity: Effects of chronic NO inhibition and NO synthases gene expression. Am J Physiol. 1998 ; 274: F791 - F798
48. Bobadilla NA, Tapia E, Franco M, et al. Role of nitric oxide in renal hemodynamic abnormalities of cyclosporin nephrotoxicity. Kidney Int. 1994 ; 46: 773-779
49. López-Ongil S, Saura M, Rodríguez-Puyol D, et al. Regulation of endothelial NO synthase expression by cyclosporin A in bovine aortic endothelial cells. Am J Physiol. 1996 ; 271 (3 Pt 2). H1072 - H1078
50. Kon V, Sugiura M, Inagami T, et al. Role of endothelin in cyclosporine-induced glomerular dysfunction. Kidney Int. 1990 ; 37: 1487-1491
51. Diederich D, Yang Z, Lüscher TF. Chronic cyclosporine therapy impairs endothelium-dependent relaxation in the renal artery of the rat. J Am Soc Nephrol. 1992 ; 2: 1291-1297
52. Nishiyama A, Kobori H, Fukui T, et al. Role of angiotensin II and reactive oxygen species in cyclosporine A-dependent hypertension. Hypertension. 2003 ; 42: 754-760
53. Burdmann EA, Andoh TF, Nast CC, et al. Prevention of experimental cyclosporin-induced interstitial fibrosis by losartan and enalapril. Am J Physiol. 1995 ; 269: F491 - F499
54. Zhou X, Crook MF, Sharif-Rodriguez W, et al. Chronic antagonism of the mineralocorticoid receptor ameliorates hypertension and end organ damage in a rodent model of salt-sensitive hypertension. Clin Exp Hypertens. 2011 ; 33: 538-547
55. Brown NJ. Eplerenone: Cardiovascular protection. Circulation. 2003 ; 107: 2512-2518
56. Luik PT, Kerstens MN, Hoogenberg K, et al. Low plasma aldosterone despite normal plasma renin activity in uncomplicated type 1 diabetes mellitus: Effects of RAAS stimulation. Eur J Clin Invest. 2003 ; 33: 787-793